Hsbc Holdings PLC Takes $3.30 Million Position in Repligen Corporation $RGEN

Hsbc Holdings PLC purchased a new position in shares of Repligen Corporation (NASDAQ:RGEN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 24,170 shares of the biotechnology company’s stock, valued at approximately $3,302,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its stake in shares of Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after buying an additional 1,091,683 shares during the last quarter. United Capital Financial Advisors LLC bought a new position in Repligen in the 3rd quarter worth $368,387,000. Opti Capital Management LP purchased a new stake in Repligen in the fourth quarter worth about $2,399,209,000. Wasatch Advisors LP lifted its stake in shares of Repligen by 27.9% in the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after purchasing an additional 346,720 shares during the period. Finally, Maverick Capital Ltd. bought a new position in shares of Repligen in the 1st quarter worth about $178,946,000. Institutional investors own 97.64% of the company’s stock.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer directly owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.60% of the company’s stock.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $176.27 on Friday. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $188.73. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The firm’s fifty day moving average is $151.99 and its two-hundred day moving average is $133.09. The company has a market cap of $9.95 billion, a P/E ratio of 241.47, a P/E/G ratio of 3.22 and a beta of 1.03.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. During the same period in the previous year, the business earned $0.26 earnings per share. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, analysts anticipate that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. JPMorgan Chase & Co. lifted their price objective on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. Jefferies Financial Group reaffirmed a “hold” rating and set a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 13th. Wolfe Research initiated coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 target price for the company. Finally, Barclays upped their price target on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $166.43.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.